Enfusion Results Presentation Deck

Strong growth trends with ongoing profitability $ in millions $34.1 1Q22 1Q22 40.2% *:enfusion $36.5 Revenue $39.2 $40.5 $41.0 2Q22 3Q22 4Q22 1Q23 YOY Growth 2Q22 3Q22 4Q22 1Q23 38.2% 34.8% 27.2% 20.0% $23.5 $23.2 1Q22 Gross Profit and Adjusted Gross Profit (1) 1Q22 $27.6 $26.0 $27.2 $25.7 2Q22 3Q22 Adjusted Gross Profit $27.5 $27.2 2Q22 4Q22 1Q23 Gross Margin and Adjusted Gross Margin 3Q22 4Q22 Gross Margin 67.8% 70.3% 69.4% 67.2% -Gross Profit $27.9 $27.7 Adjusted Gross Margin 68.9% 71.2% 70.5% 68.0% 1Q23 67.5% 68.2% (1) See appendix for non-GAAP reconciliations. $1.8 $(12.5) 1Q22 1Q22 NM Net Income and Adjusted EBITDA $5.3 $5.4 $2.6 (1) $6.8 $0.8 $(4.1) 2Q22 3Q22 4Q22 1Q23 Adjusted EBITDA -Net Income Net Income Margin and Adjusted EBITDA Margin 2Q22 3Q22 4Q22 Net Income Margin 6.6% NM 1.9% $5.7 $4.7 Adjusted EBITDA Margin 5.4% 14.5% 13.9% 16.7% 1Q23 11.5% 13.9% ($4.1) 1Q22 Operating Cash Flow and (1) Adjusted Free Cash Flow ($9.4) 1Q22 2Q22 NM $2.9 NM ($1.4) $7.8 $4.8 $7.5 $3.6 Operating Cash Flow Margin and Adjusted Free Cash Flow Conversion $4.5 3Q22 4Q22 1Q23 Adjusted FCF -Operating CF $0.9 Free Cash Flow Conversion NM 87.6% 53.4% 2Q22 3Q22 4Q22 1Q23 Operating Cash Flow Margin 7.9% 20.0% 18.6% Ⓒ2023 ENFUSION. ALL RIGHTS RESERVED. 2.3% 79.7% 11

View entire presentation